Join
Live feed
·
PRReleasevia Quantisnow
Beam Therapeutics Inc. logo

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

ByQuantisnow·Wall Street's wire, on your screen.
BEAM· Beam Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BEAM (Beam Therapeutics Inc.) and more on Quantisnow.